Iconovo receives new patent in Japan for its ICOone® inhaler platform
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the Japanese Patent Office (JPO) has issued a Notice of Allowance for yet another patent pertaining to ICOone® – an innovative inhaler platform that enables easy and cost-effective administration of vaccines and biologics. Iconovo is already running several development projects based on ICOone®, one of which is financially supported by the Bill & Melinda Gates Foundation.
Iconovo to evaluate ICOone Nasal for the development of antiviral nasal inhalation product
Iconovo AB (publ), which develops complete inhalation products for a global market announced today that it has reached an agreement with ENA Respiratory Pty Ltd to evaluate ICOone® Nasal for delivering INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of complications associated with respiratory viral infections. Iconovo is entitled to step-by-step development service fees at a total value of up to SEK 0.9 million over the coming four months, whereafter further development work will be discussed.
Iconovo utvärderar ICOone Nasal för utveckling av antiviral nasal inhalationsprodukt
Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, meddelade idag att man har ingått ett avtal med ENA Respiratory Pty Ltd om att utvärdera ICOone® Nasal för administration av INNA-051, en brett verkande immunmodulerande behandling i en ny klass som utvecklas för att förebygga komplikationer associerade med virala luftvägsinfektioner. Iconovo är berättigade till stegvis ersättning för utvecklingstjänster till ett totalt värde av upp till 0,9 miljoner kronor under de kommande fyra månaderna, varefter ytterligare utvecklingsarbete kommer diskuteras.
